No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 21 of the 40 quarters in the window, leaving 19 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 522.5x · 10Y median 61515.7x · 18th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T16:28:14.795Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T16:28:14.795Z. Latest historical point 2022-11-14.
The latest delayed quote for Palisade Bio, Inc. (PALI) stock was $1.51 as of Oct 6, 2026, 12:25 PM EDT, up 3.08% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -8.8% · 3-year avg -44.7%/yr · 5-year avg -76.0%/yr
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease.
Biotechnology · Denver, CA
Next Earnings Date
Nov 9, 2026
34 days away
EPS Estimate
-0.06
Revenue Est.
$465302.00
Last Quarter Results
EPS
$-0.05
vs Estimate
$-0.05
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PALI | $261.24M | $1.50 | +3.08% | -8.78% | -76.02% | -71.24% | N/A |
| 2LXEO | $262.65M | $3.35 | -1.91% | -48.33% | N/A | N/A | vs PALI |
| 3ANIK | $258.67M | $19.33 | -2.03% | +116.73% | -13.40% | -8.51% | vs PALI |
| 4ACIU | $256.72M | $2.52 | -6.92% | -31.95% | -16.03% | -16.61% | vs PALI |
| 5IKT | $266.05M | $2.02 | +0.75% | +20.37% | -29.10% | N/A | vs PALI |
| 6EPRX | $266.10M | $7.95 | +2.62% | +32.30% | N/A | N/A | vs PALI |
forward FY estimate
N/A
$500000.00
vs Estimate
$500000.00
Consensus Rating
Based on 9 analysts
Average Price Target
$10.22
+579.2% upside
Low
$5.00
Current
$1.50
High
$25.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.07 | $-0.06 | $-0.05 | 6 |
| Quarter ending Dec 2026 | $-0.09 | $-0.07 | $-0.06 | 6 |
| Quarter ending Mar 2027 | $-0.07 | $-0.07 | $-0.07 | 2 |
| Quarter ending Jun 2027 | $-0.07 | $-0.07 | $-0.07 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.25 | $-0.23 | $-0.20 | 7 |
| FY 2027 | $-0.40 | $-0.28 | $-0.20 | 7 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $465302.00 | $465302.00 | $465302.00 | 1 |
| Quarter ending Dec 2026 | $433012.00 | $433012.00 | $433012.00 | 1 |
| Quarter ending Mar 2027 | $402963.00 | $402963.00 | $402963.00 | 1 |
| Quarter ending Jun 2027 | $375000.00 | $375000.00 | $375000.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $428571.00 | $428571.00 | $428571.00 | 5 |
| FY 2027 | $47.71M | $47.71M | $47.71M | 7 |
